CLNN Company Profile and Key Details
Clene Inc.
CLNN Stock Price Chart
Stock Price Today
Clene Inc. (CLNN) stock declined over -2.50%, trading at $4.68 on NASDAQ, down from the previous close of $4.80. The stock opened at $4.80, fluctuating between $4.50 and $4.96 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Company Information
| Employees | 82 |
| Beta | 0.41 |
| Sales or Revenue | $654.00K |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Clene Inc. (NASDAQ: CLNN) stock price is $4.68 in the last trading session. During the trading session, CLNN stock reached the peak price of $4.96 while $4.50 was the lowest point it dropped to. The percentage change in CLNN stock occurred in the recent session was -2.5% while the dollar amount for the price change in CLNN stock was -$0.12.
The NASDAQ listed CLNN is part of Biotechnology industry that operates in the broader Healthcare sector. Clene Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Jerry Miraglia J.D.
Gen. Counsel & Corporation Sec.
Mr. Mark G. Mortenson ESQ.
Chief Science Officer
Mr. Morgan R. Brown CPA, CPA, M.B.A., MBA
Corporation Sec.
Mr. Robert Etherington MBA
Chief Executive Officer, Pres & Director
Mr. Mark G. Mortenson
Co-Founder & Chief Science Officer
Dr. Tae Heum Jeong D. Mgt.
Consultant
Ms. Mary Anne Mcneil
Head of HR
Dr. Robert Glanzman M.D.
Chief Medical Officer
Mr. Michael T. Hotchkin
Chief Devel. Officer
Dr. Benjamin M. Greenberg M.D., M.H.S.
Head of Medical
CLNN's closing price is 22.51% higher than its 52-week low of $3.82 where as its distance from 52-week high of $11.00 is -57.45%.
Number of CLNN employees currently stands at 82.
Official Website of CLNN is: https://clene.com
CLNN could be contacted at phone 801 676 9695 and can also be accessed through its website. CLNN operates from 6550 South Millrock Drive, Salt Lake City, UT 84121, United States.
CLNN stock volume for the day was 101.63K shares. The average number of CLNN shares traded daily for last 3 months was 82.31K.
The market value of CLNN currently stands at $37.35M with its latest stock price at $4.68 and 7.98M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com